Dr. Samir T. Abdelshaheed, M.D.
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 413
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
VA license 0101236853
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sentara Norfolk General Hospital Norfolk, VA
- Sentara Princess Anne Hospital Virginia Beach, VA
- Sentara Obici Hospital Suffolk, VA
- Bon Secours Maryview Medical Center Portsmouth, VA
- Bon Secours Harbour View Medical Center Suffolk, VA
Medical groups
- Family Medicine Healthcare PLLC (7 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 413
- Services billed
- 5,466
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 947 | 317 |
| Established patient office or other outpatient visit, 20-29 minutes | 910 | 306 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 252 | 39 |
| Annual depression screening, 5 to 15 minutes | 231 | 226 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 192 | 30 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 176 | 176 |
| Administration of influenza virus vaccine | 159 | 158 |
| Urinalysis, manual test | 134 | 82 |
| Injection of drug or substance under skin or into muscle | 113 | 40 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 110 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 72 payments worth $1,474 in total to this clinician.
| Pfizer Inc. | $431 |
|---|---|
| Novo Nordisk Inc | $186 |
| AbbVie Inc. | $172 |
| AstraZeneca Pharmaceuticals LP | $91.66 |
| GlaxoSmithKline, LLC. | $78.44 |
| Boston Scientific Corporation | $62.21 |
| Janssen Pharmaceuticals, Inc | $61.62 |
| Otsuka America Pharmaceutical, Inc. | $59.33 |
| Food and Beverage | $1,474 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 8 companies. The companies reported $363,317 in research payments for these studies, mostly to the institutions running them.
- A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients
Novartis Pharmaceuticals Corporation - A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clini…
AstraZeneca Pharmaceuticals LP - A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
ModernaTX, Inc. · Terminated · NCT05085366 - A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With …
Janssen Research & Development, LLC - A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with R…
AstraZeneca Pharmaceuticals LP - A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company · Completed · NCT05803421 - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
Amgen Inc. - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Amgen Inc. - A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
Novartis Pharmaceuticals Corporation - Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age
Sanofi Pasteur Inc. · Completed · NCT06641180
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.